Why the study?
How does the diagnostic performance of immunological creatine-kinase MB assay vary over time following myocardial infarction?
How does the diagnostic performance of immunological creatine-kinase MB assay vary over time following myocardial infarction?
Answers are grounded in this paper and cite their sources.
The diagnostic effectiveness of CK-MB immunoassay for myocardial infarction is optimal on the first day but declines on subsequent days due to a loss in sensitivity.
Immunoassay of creatine kinase-MB provides numerical information, which makes it possible to estimate quantitatively the diagnostic performance following myocardial infarction. Two graphical methods for such an evaluation are presented. The relationship between technical sensitivity and specificity was analyzed using a continuous function, the receiver-operator characteristic curve. Using this function, a diagnostic threshold ("upper normal limit") was chosen, which balances both technical specificity and sensitivity on the first day following infarction. On the second and third days this threshold caused a progressive loss of technical sensitivity. The relationship between effectiveness and the prevalence of myocardial infarction in the tested population was evaluated with a nomogram correlating these two quantities. With the chosen diagnostic threshold, effectiveness is independent of prevalence on the first day, but the loss in technical sensitivity on subsequent days causes effectiveness to decay when the prevalence is high.
No takes yet. Share an insight, caveat, or question.
Werner et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: